GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-24	NT$22.60	0.00%	60,600
26-08-21	NT$22.60	0.00%	71,593
26-08-20	NT$22.60	+0.44%	90,095
26-08-19	NT$22.50	+0.90%	100,679
26-08-18	NT$22.30	-0.67%	76,924

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-08-24			5-day change	1st Jan Change
22.60 ^TWD	0.00%		+0.67%	-12.23%

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

Market Cap	2.54B 79.84M 68.42M 64.01M 58.52M 110M 7.64B 112M 757M 295M 3.84B 300M 293M 12.7B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.32B 72.94M 62.51M 58.48M 53.46M 101M 6.98B 102M 692M 269M 3.51B 274M 268M 11.6B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
06-10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 week	+0.67%
Current month	+1.57%
1 month	-1.95%
3 months	-15.99%
6 months	-14.72%
Current year	-12.23%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	22.1	22.8
1 month	21.25	23.5
Current year	21.25	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	2018-12-31
Dih Fen Wu DFI	Director of Finance/CFO	-	2009-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	2012-11-11

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	2001-01-31
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	2012-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	0.00%	+0.67%	-2.16%	-17.06%	79.86M
LONZA GROUP AG	-0.74%	+3.78%	+3.74%	+23.10%	51.61B
REVOLUTION MEDICINES, INC.	+1.01%	-0.20%	+471.68%	+564.93%	44.89B
IQVIA HOLDINGS INC.	+0.16%	+7.88%	+36.14%	+20.76%	42.77B
BEONE MEDICINES AG	-0.66%	+2.61%	+18.59%	+87.04%	42.58B
CELLTRION, INC.	+0.88%	-3.48%	+17.20%	+53.83%	31.82B
MEDPACE HOLDINGS, INC.	-0.12%	+3.84%	+33.73%	+145.25%	17.33B
ASCENDIS PHARMA A/S	-0.53%	+1.84%	-	-	16.63B
EUROFINS SCIENTIFIC SE	+0.58%	+4.66%	+7.17%	+30.87%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.15%	+4.17%	+84.49%	+50.33%	14.09B
Average	+0.17%	+3.90%	+74.51%	+106.56%	27.66B
Weighted average by Cap.	+0.10%	+4.10%	+100.55%	+140.58%

	2024	2025
Net sales	14.7M 462K 396K 370K 338K 638K 44.2M 645K 4.38M 1.7M 22.19M 1.73M 1.7M 73.43M	37.86M 1.19M 1.02M 953K 871K 1.64M 114M 1.66M 11.28M 4.38M 57.15M 4.46M 4.37M 189M
Net income	-230M -7.21M -6.18M -5.78M -5.29M -9.98M -691M -10.08M -68.42M -26.6M -347M -27.08M -26.49M -1.15B	-235M -7.39M -6.33M -5.92M -5.41M -10.22M -707M -10.32M -70.06M -27.24M -355M -27.73M -27.13M -1.17B
Net Debt	-442M -13.88M -11.9M -11.13M -10.17M -19.2M -1.33B -19.4M -132M -51.2M -667M -52.12M -50.99M -2.21B	-220M -6.9M -5.91M -5.53M -5.06M -9.54M -660M -9.64M -65.44M -25.45M -332M -25.9M -25.34M -1.1B